Individuals who are known to be human immunodeficiency virus (HIV) infected are eligible (note: HIV testing is not required for entry into the study)
Patients with a known human immunodeficiency virus (HIV) infection are not eligible (HIV testing not required)
Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.
Known diagnosis of human immunodeficiency virus (HIV); (HIV testing is not required)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing is not required)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not required)
Known history of human immunodeficiency virus (HIV); testing is not required in the absence of history
Subjects with a known history of human immunodeficiency virus (HIV), including patients with controlled disease on antiretroviral therapy; HIV testing is not required as part of screening for this study
The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
Known positive serology for human immunodeficiency virus (HIV) (baseline testing not required)
Patients with known human immunodeficiency virus (HIV) infection or hepatitis B or C infection; HIV testing is not mandated and is to be performed at the discretion of the treating investigator
Known human immunodeficiency virus (HIV) positive (testing not required)
Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required. High-dose ascorbate acid is a known CYP A inducer, which results in lower serum levels of antiretroviral drugs
Subject is known to be positive for human immunodeficiency virus (HIV); HIV testing is not required
Patients known to be human immunodeficiency (HIV)-positive must not have multi-drug resistant HIV infection, CD counts < /ul or other concurrent acquired immunodeficiency syndrome (AIDS)-defining conditions; serologic screening for HIV is required within the  months prior to study enrollment
Has a known history of human immunodeficiency virus (HIV) (HIV / antibodies). No HIV testing is required unless mandated by local health authority.
Participant has known HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.
Human immunodeficiency virus (HIV) infection as detected through any laboratory method (e.g., enzyme-linked immunosorbent assay, Western Blot, RNA PCR). [Note: Testing to confirm the absence of HIV infection is required at screening unless testing was performed by the local laboratory within  months prior to screening.]
Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.
Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV infected patients.
Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study)
Participant has known Human Immunodeficiency Virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.
Known to be positive for the human immunodeficiency virus (HIV); note: HIV-testing is not required for eligibility, but if performed previously and was positive, the subject is ineligible
A known history of human immunodeficiency virus(HIV) seropositivity or known immunodeficiency; HIV testing will not be required as part of this trial, unless HIV is clinically suspected
Human immunodeficiency virus (HIV) infection confirmed by nucleic acid testing (NAT)
Human immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testing
Known human immunodeficiency virus (HIV) seropositivity\r\n* Note: HIV testing is not required
The subject is known to be positive for the human immunodeficiency virus (HIV); Note: baseline HIV screening is not required
For dose-escalation cohort only, known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required; HIV positive patients will be eligible for the dose-expansion cohort
Known human immunodeficiency virus (HIV) seropositivity\r\n* Note: HIV testing is not required
Known human immunodeficiency virus (HIV) positive (testing not required).
Known positivity for human immunodeficiency virus (HIV); Note: baseline testing for HIV is not required
Known to be seropositive for human immunodeficiency virus (HIV); an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
Known history of human immunodeficiency virus (HIV) infection. Testing for HIV status is not necessary unless clinically indicated
Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV-infected participants
Patients with known human immunodeficiency virus (HIV), hepatitis B or C infections; testing to prove negative status is not required for enrollment unless it is deemed necessary for usual medical care of the patient
Known positive for human immunodeficiency virus (HIV); baseline HIV screening is not required
Known human immunodeficiency virus (HIV) infection (pre-study testing not required)
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Known HIV (HIV testing will be performed at screening if required by local regulations) in participants to be pretreated with obinutuzumab
Has a congenital or acquired immunodeficiency, including subjects with known history of infection with human immunodeficiency virus (HIV) NOTE: HIV-positive subjects who are taking antiretroviral therapy are ineligible due to potential PK interactions with tazemetostat.
Patients who are human immunodeficiency virus (HIV)+ (HIV+ patients registered at Fred Hutchinson Cancer Research Center [FHCRC] should be offered treatment on Protocol )
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Known human immunodeficiency virus infection (pre-study testing not required)
All patients must be willing to undergo testing for human immunodeficiency virus (HIV) testing if not tested within the past  months
Has a known history of human immunodeficiency virus (HIV) (HIV / antibodies); Note: testing not required at baseline unless clinically indicated
Have a known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history.
Known human immunodeficiency virus (HIV) infected patients (HIV testing will not be performed as a part of screening) on combination antiretroviral therapy are eligible for inclusion; the use of zidovudine is not allowed
Patients known to be human immunodeficiency virus (HIV) positive; HIV testing is not required in the absence of clinical signs and symptoms suggesting HIV infection
Participants known to be human immunodeficiency virus (HIV) positive; testing is not required in the absence of clinical signs and symptoms suggesting HIV infection
No human immunodeficiency virus (HIV) infection; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; patients who test positive or who are known to be infected are not eligible; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
Prior history of HIV-positivity (routine HIV testing is not required pre-treatment)
The subject is known to be positive for the human immunodeficiency virus (HIV); Note: baseline HIV screening is not required
Patients with known human immunodeficiency virus (HIV) must have a CD count >  and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
Known human immunodeficiency virus (HIV) infection or a known HIV-related malignancy. Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C (NOTE: testing is not required)\r\n* Known human immunodeficiency virus (HIV) infection (NOTE: testing is not required)\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within  weeks of first dose of mirvetuximab soravtansine
Known infection with human immunodeficiency virus (HIV) or subject has tested positive for HIV; patients without prior HIV testing will not be required to be tested
Known diagnosis of human immunodeficiency virus (HIV) infection; testing is not required for participation
Known HIV positivity (testing not required).
Known human immunodeficiency virus (HIV) infection; testing prior to enrollment is not required
Known positivity for human immunodeficiency virus (HIV); note: baseline testing for HIV is not required
Patients may not be known to be human immunodeficiency virus (HIV)-positive; HIV testing is not required for study participation
Known seropositive for human immunodeficiency virus (HIV); HIV testing is not required; hepatitis testing is not required
Known human immunodeficiency virus (HIV) infection (pre-study testing not required)
Known history of human immunodeficiency virus (HIV). Subjects should be tested for HIV prior to Randomization if required by local regulations or EC;
Human immunodeficiency virus (HIV) infection; patients should provide consent for HIV testing according to the institution's standard practice
Participants with a known diagnosis of human immunodeficiency virus (HIV); Note: an HIV screening test does not have to be performed to evaluate this criterion
Known diagnosis of human immunodeficiency virus (HIV); Note: An HIV screening test does not have to be performed to evaluate this criterion
Known human immunodeficiency virus (HIV) infection (HIV testing not required)
The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
Known human immunodeficiency virus (HIV) positive (testing not required).